Michael Kors scoops up Jimmy Choo to keep pace with Coach, and Lululemon's back after a spring mishap, could its winning days continue? We hit these retail news items and check in on Chipotle's food-borne illness problems ahead of earnings.

For years after the financial crisis, bank earnings fluctuated wildly due to high loan losses, volatile markets, and elevated legal expenses. Fortunately, this trend seems to have come to an end, as the results from the second quarter demonstrate.

OPEC’s production cut compliance continues to drop, is this the end of its attempt to prop up oil prices?

After Puma Biotech's recent success, the search is on for other clinical-stage biotech stocks being run by proven CEOs. Could experience turn Aurinia Pharmaceuticals, Axovant Sciences, and Esperion Therapeutics into winners too?

Thanks to Slack for supporting Motley Fool. Learn more at slack.com.

We field Foolish questions from the world of consumer and retail. First, Levi wants to know about the prospects for apparel retailer Buckle (and its double-digit dividend yield). Meanwhile, Shubhra is curious about Kirkland Signature and why the Costco private label is available on Amazon.com.

Thanks to Harry’s for supporting Industry Focus. Get your Free Trial Set -- go to Harrys.com/fool.

Brian Patrick Eha, author of How Money Got Free, joins Gaby Lapera to discuss cryptocurrencies, tokens, blockchain technology, and what it all means for investors, regulators, and financial systems.

Thanks to Slack for supporting Motley Fool. Learn more at slack.com.

We love covering IPOs, but we can't bring ourselves to buy a stock that's only been publicly traded for a few months. We explain why on the final episode of "never will I ever week."

 We all make investing mistakes, but buying a commodity producer lacking a cost advantage shouldn’t be one of them.

Only 10% of drugs make it across the FDA finish line from phase 1 clinical trials, making acquiring pre-clinical biotech stocks the riskiest game in town.

We continue with our theme for this week, as Asit Sharma explains the major hurdles day traders and speculators face in their pursuit of easy profits.